Tyrosine kinase 2 variant influences T lymphocyte polarization and multiple sclerosis susceptibilityNicolas Couturier, David Brassat, Florence Bucciarelli et al.|Brain|2011Cited by 113
Natalizumab Versus Fingolimod in Patients with Relapsing-Remitting Multiple Sclerosis: A Subgroup Analysis From Three International CohortsSifat Sharmin, Éric Berger, Raed Alroughani et al.|CNS Drugs|2021Cited by 12
Impact of methodological choices in comparative effectiveness studies: application in natalizumab versus fingolimod comparison among patients with multiple sclerosisMathilde Lefort, F. Grand’Maison, Sifat Sharmin et al.|BMC Medical Research Methodology|2022Cited by 6